GURUFOCUS.COM » STOCK LIST » USA » NAS » Enanta Pharmaceuticals Inc (NAS:ENTA) » Definitions » Profitability Rank
Switch to:

Enanta Pharmaceuticals Profitability Rank

: 7 (As of Jun. 2022)
View and export this data going back to 2013. Start your Free Trial

Enanta Pharmaceuticals has the Profitability Rank of 7.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Enanta Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2022 was -167.05%. As of today, Enanta Pharmaceuticals's Piotroski F-Score is 3.


Competitive Comparison

For the Biotechnology subindustry, Enanta Pharmaceuticals's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Enanta Pharmaceuticals Profitability Rank Distribution

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's Profitability Rank falls into.



Enanta Pharmaceuticals Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Enanta Pharmaceuticals has the Profitability Rank of 7.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Enanta Pharmaceuticals's Operating Margin % for the quarter that ended in Jun. 2022 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2022 ) / Revenue (Q: Jun. 2022 )
=-32.54 / 19.479
=-167.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Enanta Pharmaceuticals has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Enanta Pharmaceuticals Profitability Rank Related Terms

Thank you for viewing the detailed overview of Enanta Pharmaceuticals's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Enanta Pharmaceuticals Business Description

Enanta Pharmaceuticals logo
Traded in Other Exchanges
Address
500 Arsenal Street, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Executives
Russell Lesley director 41 MOORES RD. FRAZER PA 19355
Peterson Kristine director AMARIN CORPORATION MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE MYSTIC CT 06355
Foletta Mark G director AMYLIN PHARMACEUTICALS INC 9360 TOWNE CENTRE DR SAN DIEGO CA 92121
Hata Yujiro S director C/O XENCOR, INC. 111 WEST LEMON AVENUE MONROVIA CA 91016
Luu Brendan officer: Sr. VP, Business Dev. C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472
Kieffer Tara Lynn officer: Sr. VP, New Product Dev. C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472
Adda Nathalie officer: Sr. VP & Chief Medical Officer C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472
Gardiner Nathaniel S. director C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472
Golumbeski George director C/O CELGENE CORP. 86 MORRIS AVENUE SUMMIT NJ 07901
Ocain Tim officer: Senior Vice President C/O ENANTA PHARMACEUTICALS, INC. 500 ARSENAL STREET WATERTOWN MA 02472
Carter Bruce L A director C/O ZYMOGENETICS, INC. 1201 EASTLAKE AVENUE SEATTLE WA 98102
Saints Capital Granite, L.p. 10 percent owner 475 SANSOME STREET SUITE 1850 SAN FRANCISCO CA 94111
Saints Capital Granite, Llc 10 percent owner 475 SANSOME STREET, SUITE 1850 SAN FRANCISCO CA 94111
Obp (bermuda) Iii - Holdings Llc 10 percent owner 475 SANSOME STREET, SUITE 1850 SAN FRANCISCO CA 94111
Mrna - Holdings Llc 10 percent owner 475 SANSOME STREET, SUITE 1850 SAN FRANCISCO CA 94111

Enanta Pharmaceuticals Headlines

From GuruFocus

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)